Emerging patient-specific treatment modalities in head and neck cancer - a systematic review.

Eliçin, Olgun; Cihoric, Nikola; Vlaskou Badra, Eugenia; Ozsahin, Mahmut (2019). Emerging patient-specific treatment modalities in head and neck cancer - a systematic review. Expert opinion on investigational drugs, 28(4), pp. 365-376. Taylor & Francis 10.1080/13543784.2019.1582642

Full text not available from this repository.

INTRODUCTION

Head and neck cancer (HNC) is an immunosuppressive disease that demonstrates heterogeneous molecular characteristics and features of tumor-host interaction. Beside radiotherapy and surgery, the current standard of care in systemic treatment involves the use of cytotoxic chemotherapy, monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs). There are also other modalities being developed under the category of immunotherapy, but they are overshadowed by the recent advancements of immune checkpoint inhibitors. Areas Covered: This systematic review covers recent advancements in "patient-specific" treatment modalities, which can be only administered to a given patient. Expert Opinion: Currently, patient-specific treatment modalities in HNC mainly consist of active immunotherapy using adoptive cell therapies and/or gene engineered vectors. Despite the slow pace of development, the interest continues in these treatment modalities. The future of HNC treatment is expected to be guided by biomarkers and personalized approaches with tailored combinations of local treatments (radiotherapy, surgery), systemic agents and immune system modulation. Systematic research is required to generate robust data and obtain a high-level of evidence for the effectiveness of such treatment modalities.

Item Type:	Journal Article (Review Article)
Division/Institute:	04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology
UniBE Contributor:	Eliçin, Olgun, Cihoric, Nikola, Vlaskou Badra, Eugenia
Subjects:	600 Technology > 610 Medicine & health
ISSN:	1744-7658
Publisher:	Taylor & Francis
Language:	English
Submitter:	Beatrice Scheidegger
Date Deposited:	21 May 2019 09:24
Last Modified:	05 Dec 2022 15:26
Publisher DOI:	10.1080/13543784.2019.1582642
PubMed ID:	30760055
Uncontrolled Keywords:	CAR T-cells CRISPR adoptive cell therapy cancer vaccine clinical trials gene editing head and neck cancer squamous-cell carcinoma targeted therapy
URI:	https://boris.unibe.ch/id/eprint/126805